Patients are randomized to receive either the triple combination tablet (Trizivir) or to receive Combivir plus abacavir as a separate tablet. Patients take their study medications for 24 weeks.

Inclusion Criteria

Patients may be eligible for this study if they:

• Are at least 18 years old.
• Are HIV-positive.
• Are currently receiving one of the following anti-HIV drug combinations: Combivir plus abacavir, Combivir plus abacavir plus a protease inhibitor, or Combivir plus abacavir plus a non-nucleoside reverse transcriptase inhibitor (NNRTI). Patients must have been taking this drug combination for at least the past 16 weeks. This also must be the first anti-HIV drug combination the patient has received.
• Have a viral load (level of HIV in the blood) less than or equal to 400 copies/ml.
• Have CD4+ cell count greater than 200 cells/mm3.
• Agree to use effective methods of birth control.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have been diagnosed with AIDS.
• Have a gastrointestinal disorder that makes it difficult for patients to absorb food or to take medications by mouth.
• Have hepatitis.
• Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease.
• Are allergic to any of the study drugs.
• Abuse alcohol or drugs.
• Will not be available for the entire 24-week study period.
• Are pregnant or breast-feeding.
• Have taken or will need to take certain medications, including radiation therapy, chemotherapy, drugs that affect the immune system (such as interleukin), an HIV vaccine, foscarnet, and hydroxyurea.
• Are enrolled in another experimental drug study.